Free Trial
→ This high yielding “gold annuity” is starting to move… (From Golden Portfolio) (Ad)tc pixel
NASDAQ:CERS

Cerus Q3 2026 Earnings Date & Estimates

Cerus logo
$2.30 +0.02 (+0.88%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$2.30 0.00 (-0.22%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cerus is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cerus in Q3 2026

Cerus is expected to post earnings of -$0.0125 per share on revenue of $63.25 million. In the same quarter a year earlier Cerus reported -$0.0002 per share on revenue of $60.24 million. Cerus last reported on July 30, 2026, posting -$0.01 per share and beating the -$0.0133 consensus estimate. Cerus has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.0125
Expected Revenue
$63.25 million
Prior-Year EPS
-$0.0002
Prior-Year Revenue
$60.24 million
Expected Revenue Growth
+5.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.01 (Beat by +$0.0033)
Last Quarter Revenue
$63.30 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Cerus Q3 2026 Earnings FAQ

Cerus (NASDAQ:CERS) is scheduled to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes.

Cerus' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Cerus to post earnings of -$0.0125 per share for Q3 2026.

The consensus revenue estimate for Cerus is $63.25 million for Q3 2026.

Cerus Earnings Headlines

Contrasting TransMedics Group (NASDAQ:TMDX) and Cerus (NASDAQ:CERS)
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090111
Head to Head Survey: Cerus (NASDAQ:CERS) versus Bausch + Lomb (NYSE:BLCO)
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086062
This high yielding “gold annuity” is starting to move…
Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields up 1,298%, Reunion Gold up 716%, and Highlander Silver up 741%. Now he has released a new research report on a unique high yielding gold security backed by what he calls the world's best gold mine today, offering a yield now plus long term upside.tc pixel
October 10 at 1:00 AM  |  Golden Portfolio (Ad)
Cerus: This Blood-Safety Underdog Should Be Earning More Respect
August 18, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4937729-cerus-this-blood-safety-underdog-should-be-earning-more-respect?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Cerus Corporation 2026 Q2 - Results - Earnings Call Presentation
August 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933799-cerus-corporation-2026-q2-results-earnings-call-presentation
Cerus outlines $229M-$231M 2026 product revenue outlook as IFC guidance rises to $23M-$25M
July 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4622368-cerus-outlines-229m-231m-2026-product-revenue-outlook-as-ifc-guidance-rises-to-23m-25m
See More Cerus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cerus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cerus and other key companies, straight to your email.

About Cerus

Cerus (NASDAQ:CERS) is a biomedical products company that develops and commercializes technologies intended to improve the safety of donated blood components. Its primary platform is the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections by inactivating viruses, bacteria, parasites and contaminating white blood cells in donated blood products.

The INTERCEPT portfolio includes systems for treating platelet and plasma components, as well as technologies developed for red blood cells. The products use a combination of a pathogen-inactivating compound and illumination to target genetic material from pathogens, helping prevent replication while preserving the blood component for transfusion. Cerus sells its products to blood centers, hospitals and other transfusion-related organizations.

Founded in 1991 and headquartered in Concord, California, Cerus serves customers in the United States and international markets, including Europe and other regions where its products have received applicable regulatory approvals. The company’s products are marketed under regulatory clearances and approvals from agencies such as the U.S. Food and Drug Administration and European authorities.

View Cerus Profile
Earnings Tools